Product Information
AZITHROMYCIN 200 MG/5 ML SUSP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.2046 per ML under NDC 00093202631. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 5, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/5mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093202631
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AZITHROMYCIN MONOHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA065246FDA Approved
7/5/2006
TE Code
AB
On Market Since
12/17/2010
Pharmacological Classes
Price Statistics
The NADAC for AZITHROMYCIN 200 MG/5 ML SUSP has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 35.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2046 per ML |
|---|---|
| All-time high | $0.5166 (Mar 11, 2015) |
| All-time low | $0.1802 (Nov 20, 2024) |
| 52-week high | $0.2206 |
| 52-week low | $0.2046 |
| Median price | $0.3105 |
| Average price | $0.3282 |
| Largest weekly change | +26.2% (Jun 18, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Azithromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AZITHROMYCIN 200 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for AZITHROMYCIN 200 MG/5 ML SUSP, manufactured by Teva Pharmaceuticals USA Inc., is $0.2046 per ML (NDC 00093202631), effective Sep 30, 2026.
How has the price of AZITHROMYCIN 200 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for AZITHROMYCIN 200 MG/5 ML SUSP has declined 35.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AZITHROMYCIN 200 MG/5 ML SUSP?
Since Nov 28, 2013, the NADAC for AZITHROMYCIN 200 MG/5 ML SUSP has ranged from a low of $0.1802 (Nov 20, 2024) to a high of $0.5166 (Mar 11, 2015), with a median of $0.3105 per ML.
Are there cheaper alternatives to AZITHROMYCIN 200 MG/5 ML SUSP?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as AZITHROMYCIN 200 MG/5 ML SUSP in a comparable dosage form, but none are currently priced below it.
Who manufactures AZITHROMYCIN 200 MG/5 ML SUSP?
AZITHROMYCIN 200 MG/5 ML SUSP (NDC 00093202631) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.